Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial - Hoglund, Richard M; Pyae Phyo, Aung; Lek, Dysoley; Anvikar, Anupkumar R; Satpathi, Parthasarathi; Satpathi, Sanghamitra; Behera, Prativa Kumari; Tripura, Amar; Baidya, Subrata; Chau, Nguyen Hoang; Sovann, Yok; Mao, Sivanna; et al. (The Lancet (British edition), 2020)
Keywords: Adolescent; Adult; Amodiaquine; Amodiaquine - administration & dosage; Amodiaquine - therapeutic use; Anthraquinones - administration & dosage; Anthraquinones - therapeutic use; Antimalarials - administration & dosage; Antimalarials - therapeutic use; Artemether; Artemether, Lumefantrine Drug Combination - administration & dosage; Artemether, Lumefantrine Drug Combination - therapeutic use; Artemisinin; Artemisinins - administration & dosage; Artemisinins - therapeutic use; Artesunate; Charities; Clinical trials; Combination therapy; Dihydroartemisinin; Drug dosages; Drug Resistance; Drug Therapy, Combination; Drugs; EKG; Electrocardiography; Female; Fever; Health services; Humans; Laboratories; Malaria; Malaria, Falciparum - drug therapy; Male; Medical research; Mefloquine; Mefloquine - administration & dosage; Mefloquine - therapeutic use; Multidrug resistant organisms; Oral administration; Parasites; Patients; Plasmodium falciparum; Plasmodium falciparum - drug effects; Polymerase Chain Reaction; Quinolines - administration & dosage; Quinolines - therapeutic use; Randomization; Risk; Treatment Outcome; Vector-borne diseases; Vomiting; Young Adult; Myanmar; Cambodia; Congo (Kinshasa); United Kingdom; Thailand; Laos; India; Bangladesh; Vietnam; Myanmar (Burma); Asia; Africa